ECR–ISCP Partnership Announcement : European Cardiology Review partners with the International Society of Cardiovascular Pharmacotherapy

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare:

For permissions and non-commercial reprint enquiries, please visit to start a request.

For author reprints, please email
Average (ratings)
No ratings
Your rating
Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

I am delighted to announce that European Cardiology Review (ECR) has now started a partnership with the International Society of Cardiovascular Pharmacotherapy (ISCP), a leading non-for-profit organisation devoted to medical education in the field of cardiovascular therapy.

The mission of the ISCP – an associate member of the World Heart Federation – is to foster research initiatives and develop educational programmes on topics related to cardiovascular pharmacology and pharmacotherapy. With representatives from over 35 countries worldwide in its ranks, the ISCP represents an important forum for vital discussions on cardiovascular pharmacotherapy. Among many educational activities, the ISCP supports two major initiatives, namely the Cardiovascular Pharmacotherapy Book Series, with the publication of an average of six volumes on the treatment of cardiovascular conditions per year, and the ISCP Annual Scientific Sessions, which attract a large audience of medical practitioners and healthcare professionals from the world over. The ISCP holds approximately 12 regional meetings annually, aimed at discussing novel issues in the field of cardiovascular and pharmacology and therapy.

Starting in this issue, each volume of ECR will contain a Cardiovascular Pharmacotherapy section that will be jointly edited by the president of the ISCP and myself. This section will publish review articles as well as original systematic reviews and meta-analyses on the most important developments in cardiovascular pharmacotherapy. Recent outstanding clinical trials, with the potential to change clinical practice, will be presented and discussed by international experts in the field. We also plan to include editorial articles written by the president of the ISCP that will highlight important developments in the field and their potential impact on clinical practice. In addition, we will publish ‘expert opinion’ articles, which will be accompanied by brief scholarly comments by other experts and online interviews with key scientists and opinion leaders.

This is an exciting project that both ECR and ISCP are embracing with optimism, determination and great enthusiasm. We hope that our readers will find this new initiative valuable for their day-to-day practice as well as a means to gain insight into the new developments in the field of cardiovascular pharmacotherapy.